Antiplatelet drug may be better than aspirin in preventing recurrent strokes
Posted on
March 01, 2010 by
Sherry H.
American Stroke Association late-breaking science report:
SAN ANTONIO, Feb. 26, 2010 — The antiplatelet drug cilostazol — used in the United States to treat leg pain associated with peripheral vascular disease — was more effective and safer than aspirin at preventing recurrent strokes in a Japanese trial presented as late-breaking science at the American Stroke Association’s International Stroke Conference 2010.
“This study demonstrated for the first time that cilostazol significantly reduces the risk of recurrent ischemic [blood-clot caused] stroke and the incidence of serious cerebral hemorrhage, compared to aspirin,” said Yukito Shinohara, M.D., lead author of the study and head of neurology at Tachikawa Hospital in Tokyo, Japan.
